TipRanks
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
US Market
BBIO
BridgeBio Pharma
RESEARCH TOOLSreports
Want to see BBIO full AI Analyst Report?

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

1,533 Followers
See the Price Targets and Ratings of:

BBIO Analyst Ratings

Strong Buy
18Ratings
Strong Buy
17 Buy
1 Hold
0 Sell
Based on 18 analysts giving stock ratings to
BridgeBio
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$110.24
▲(37.11% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $110.24 with a high forecast of $156.00 and a low forecast of $92.00. The average price target represents a 37.11% change from the last price of $80.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","157":"$157","78.25":"$78.3","104.5":"$104.5","130.75":"$130.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":156,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$156.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.23529411764706,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$110.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,78.25,104.5,130.75,157],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.91,73.76307692307692,80.61615384615385,87.46923076923076,94.32230769230769,101.17538461538462,108.02846153846153,114.88153846153845,121.73461538461538,128.5876923076923,135.44076923076923,142.29384615384615,149.1469230769231,{"y":156,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.91,70.24271493212669,73.5754298642534,76.90814479638009,80.24085972850679,83.57357466063348,86.90628959276017,90.23900452488687,93.57171945701357,96.90443438914028,100.23714932126697,103.56986425339366,106.90257918552035,{"y":110.23529411764706,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.91,68.84,70.77,72.7,74.63,76.56,78.49,80.42,82.35,84.28,86.21,88.14,90.07,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.24,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.56,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.09,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.57,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.91,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$156.00Average Price Target$110.24Lowest Price Target$92.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on BBIO
Joon Lee
UBS
UBS
$82→$92
Buy
14.43%
Upside
Reiterated
10/16/26
BridgeBio Pharma (BBIO) Receives a New Rating from a Top Analyst
Wells Fargo Analyst forecast on BBIO
Yanan Zhu
Wells Fargo
Wells Fargo
$102
Buy
26.87%
Upside
Reiterated
10/15/26
Wells Fargo Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
H.C. Wainwright Analyst forecast on BBIO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$120
Buy
49.25%
Upside
Reiterated
10/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on BBIO
Luca Issi
RBC Capital
RBC Capital
$100
Buy
24.38%
Upside
Reiterated
10/08/26
RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Barclays Analyst forecast on BBIO
Eliana Merle
Barclays
Barclays
$157→$156
Buy
94.03%
Upside
Reiterated
10/07/26
BridgeBio Pharma (BBIO) Receives a Buy from Barclays
William Blair Analyst forecast on BBIO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
10/06/26
Analyst Reiterates Buy on BridgeBio as Multiple Late-Stage Catalysts and Infigratinib Priority Review Drive Diversified Growth Outlook
Bank of America Securities Analyst forecast on BBIO
Jason Zemansky
Bank of America Securities
Bank of America Securities
$104
Buy
29.35%
Upside
Reiterated
10/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on BBIO
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$106
Buy
31.84%
Upside
Reiterated
10/06/26
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (NASDAQ: BBIO) and Vaxcyte (NASDAQ: PCVX)
TD Cowen Analyst forecast on BBIO
Tyler Van Buren
TD Cowen
TD Cowen
$110
Buy
36.82%
Upside
Reiterated
09/24/26
Analysts Are Bullish on These Healthcare Stocks: Mediwound (MDWD), BridgeBio Pharma (BBIO)
Evercore ISI Analyst forecast on BBIO
Cory Kasimov
Evercore ISI
Evercore ISI
$130
Buy
61.69%
Upside
Reiterated
09/14/26
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
Jefferies Analyst forecast on BBIO
Andrew Tsai
Jefferies
Jefferies
$110
Buy
36.82%
Upside
Reiterated
08/31/26
Jefferies Remains a Buy on BridgeBio Pharma (BBIO)
Mizuho Securities Analyst forecast on BBIO
Salim Syed
Mizuho Securities
Mizuho Securities
$96→$110
Buy
36.82%
Upside
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Piper Sandler Analyst forecast on BBIO
Biren Amin
Piper Sandler
Piper Sandler
$115
Buy
43.03%
Upside
Reiterated
08/31/26
Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Cantor Fitzgerald Analyst forecast on BBIO
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$110
Buy
36.82%
Upside
Reiterated
08/29/26
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)
J.P. Morgan Analyst forecast on BBIO
Anupam Rama
J.P. Morgan
J.P. Morgan
$100→$111
Buy
38.06%
Upside
Assigned
08/12/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on BBIO
Joon Lee
UBS
UBS
$82→$92
Buy
14.43%
Upside
Reiterated
10/16/26
BridgeBio Pharma (BBIO) Receives a New Rating from a Top Analyst
Wells Fargo Analyst forecast on BBIO
Yanan Zhu
Wells Fargo
Wells Fargo
$102
Buy
26.87%
Upside
Reiterated
10/15/26
Wells Fargo Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
H.C. Wainwright Analyst forecast on BBIO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$120
Buy
49.25%
Upside
Reiterated
10/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on BBIO
Luca Issi
RBC Capital
RBC Capital
$100
Buy
24.38%
Upside
Reiterated
10/08/26
RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Barclays Analyst forecast on BBIO
Eliana Merle
Barclays
Barclays
$157→$156
Buy
94.03%
Upside
Reiterated
10/07/26
BridgeBio Pharma (BBIO) Receives a Buy from Barclays
William Blair Analyst forecast on BBIO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
10/06/26
Analyst Reiterates Buy on BridgeBio as Multiple Late-Stage Catalysts and Infigratinib Priority Review Drive Diversified Growth Outlook
Bank of America Securities Analyst forecast on BBIO
Jason Zemansky
Bank of America Securities
Bank of America Securities
$104
Buy
29.35%
Upside
Reiterated
10/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on BBIO
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$106
Buy
31.84%
Upside
Reiterated
10/06/26
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (NASDAQ: BBIO) and Vaxcyte (NASDAQ: PCVX)
TD Cowen Analyst forecast on BBIO
Tyler Van Buren
TD Cowen
TD Cowen
$110
Buy
36.82%
Upside
Reiterated
09/24/26
Analysts Are Bullish on These Healthcare Stocks: Mediwound (MDWD), BridgeBio Pharma (BBIO)
Evercore ISI Analyst forecast on BBIO
Cory Kasimov
Evercore ISI
Evercore ISI
$130
Buy
61.69%
Upside
Reiterated
09/14/26
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
Jefferies Analyst forecast on BBIO
Andrew Tsai
Jefferies
Jefferies
$110
Buy
36.82%
Upside
Reiterated
08/31/26
Jefferies Remains a Buy on BridgeBio Pharma (BBIO)
Mizuho Securities Analyst forecast on BBIO
Salim Syed
Mizuho Securities
Mizuho Securities
$96→$110
Buy
36.82%
Upside
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Piper Sandler Analyst forecast on BBIO
Biren Amin
Piper Sandler
Piper Sandler
$115
Buy
43.03%
Upside
Reiterated
08/31/26
Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Cantor Fitzgerald Analyst forecast on BBIO
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$110
Buy
36.82%
Upside
Reiterated
08/29/26
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)
J.P. Morgan Analyst forecast on BBIO
Anupam Rama
J.P. Morgan
J.P. Morgan
$100→$111
Buy
38.06%
Upside
Assigned
08/12/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

3 Months
Cory KasimovEvercore ISI
Success Rate
12/17 ratings generated profit
71%
Average Return
+13.81%
Copying Cory Kasimov's trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +13.81% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
20/26 ratings generated profit
77%
Average Return
+59.72%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +59.72% per trade.
2 Years
Anupam RamaJ.P. Morgan
Success Rate
23/26 ratings generated profit
88%
Average Return
+96.74%
Copying Anupam Rama's trades and holding each position for 2 Years would result in 88.46% of your transactions generating a profit, with an average return of +96.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
18
14
7
9
15
Buy
21
23
31
26
20
Hold
5
6
3
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
43
41
37
36
In the current month, BBIO has received 35 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 110.24.
Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.57 with a range of -$0.81 to -$0.28. The previous quarter’s EPS was -$0.78. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.
Next quarter’s earnings estimate for BBIO is -$0.57 with a range of -$0.81 to -$0.28. The previous quarter’s EPS was -$0.78. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $281.10M with a range of $248.03M to $347.40M. The previous quarter’s sales results were $243.68M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.
Next quarter’s sales forecast for BBIO is $281.10M with a range of $248.03M to $347.40M. The previous quarter’s sales results were $243.68M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 110.24.
    What is BBIO’s upside potential, based on the analysts’ average price target?
    BridgeBio Pharma Inc has 37.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BBIO a Buy, Sell or Hold?
          BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
            What is BridgeBio Pharma Inc’s price target?
            The average price target for BridgeBio Pharma Inc is 110.24. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $156.00 ,the lowest forecast is $92.00. The average price target represents 37.11% Increase from the current price of $80.4.
              What do analysts say about BridgeBio Pharma Inc?
              BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of BBIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.